Iblias - summary of medicine characteristics

wder and solvent for solution for injection.

Powder: solid, white to slightly yellow.

Solvent: water for injections, a clear solution.

4. CLINICAL PARTICULARS4.1 Therapeutic indications

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Iblias can be used for all age groups.

4.2 Posology and method of administration

Treatment should be under the supervision of a physician experienced in the treatment of haemophilia.

Posology

The dose and duration of the substitution therapy depend on the severity of the factor VIII d on the location and extent of the bleeding and on the patient's clinical condition.

The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma).

One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one mL of normal human plasma.

On Demand Treatment

The calculation of the required dose of factor VIII is based on the empirical finding that

1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by 1.5% to 2.5% of normal activity.

The required dose is determined using the following formulae:

Required units = body weight (kg) x desired factor VIII rise (% or IU/dL) x reciprocal of observed recovery (i.e. 0.5 for recovery of 2.0%).

The amount to be administered and the frequency of administration should always be targeted to the clinical effectiveness required in the individual case.

In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given level (in % of normal) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:

Table 1: Guide for dosing in b eeding episodes and surgery

Prophylaxis

For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses for adolescents (> 12 years age) and adult patients are 20 to 40 IU of Tblias per kg body weight two to three times per week.

In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.

Previously untreated patients

The safety and efficacy of Iblias in previously untreated patients have not yet been established.

Limited data are available.

Paediatric population

A safety and efficacy study has been performed in children of 0–12 years (see section 5.1); limited data are available for children below 1 year.

The recommended prophylaxis doses are 20–50 IU/kg twice weekly, three times weekly or every other day according to individual requirements. For paediatric patients above the age of 12, the dose recommendations are the same as for adults.

Method of administration

Intravenous use.

Iblias should be injected intravenously over 2 to 5 minutes depending on the total volume. The rate of administration should be determined by the patient’s comfort level (maximal rate of infusion: 2 mL/min).

For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the package leaflet.

4.3 Contraindications

• • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• • Known allergic reactions to mouse or hamster proteins.

4.4 Special warnings and precautions for use

Hypersensitivity

Allergic type hypersensitivity reactions are possible with Iblias.

If symptoms of hypersensitivity occur, patients should be advised to discontinue the use of the medicinal product immediately and contact their physician.

Patients should be informed of the early signs of hypersensitivity reactions including hives, nausea, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis.

In case of shock, standard medical treatment for shock should be implemented.

Inhibitors

The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per mL of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 20 exposure days. Rarely, inhibitors may develop after the first 100 exposure days.

Cases of recurrent inhibitor (low titre) have been observed after switching from one factor VIII product to another in previously treated patients with more than 100 exposure days who have a previous history of inhibitor development. Therefore, it is recommended to monitor all patients carefully for inhibitor occurrence following any product switch.

The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre inhibitors which are transiently present or remain consistently low titre posing less risk of insufficient clinical response than high titre inhibitors.

In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests.

If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered. Management of such patients should be directed by physicians with experience in the care of haemophilia andr VIII inhibitors.

Haemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascvents as non-haemophilic patients when clotting has been normalised by treatment with FVIII.ation of FVIII levels following administration, in particular in those with existing cardiovascular risk factors, might cause a patient to have the same risk for vessel closure or myocardial infarction as for the non-haemophilic population. Consequently, patients should be evaluated for cardiac risk factors.

'atheter-related complications

If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered. These complications have not been associated with the product itself.

Documentation

It is strongly recommended that every time Iblias is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the medicinal product.

Paediatric population

The listed warnings and precautions apply both to adults and children.

Sodium content

For 250/500/1000 IU strength:

After reconstitution this medicinal product contains 0.081 mmol sodium per vial of reconsti solution (corresponding to 1.86 mg per vial). This medicinal product contains less than 1 sodium (23 mg) per dose, i.e. essentially ‘sodium- free’.

For 2000/3000 IU strength:

After reconstitution this medicinal product contains 0.156 mmol sodium per vial of reconstituted

solution (corresponding to 3.59 mg per vial). This medicinal product contain sodium (23 mg) per dose, i.e. essentially ‘sodium- free’.

• 4.5 Interactions with other medicinal products and other forms of interaction

  other medicinal products have

  
  

No interactions of human coagulation factor VIII (rDNA been reported.

4.6 Fertility, pregnancy and lactation

Pregnancy

Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy is not available. Animal reproduction studies have not been conducted with factor VIII.

Therefore, factor VIII should be used during pregnancy only if clearly indicated.

It is unknown whether Iblias is excreted in human milk. The excretion in animals has not been studied. Therefore, factor VIII should be used during breast-feeding only if clearly indicated.

Fertility

No animal fertility studies have been conducted with Iblias and its effect on human fertility has not been established in controlled clinical trials. Since Iblias is a replacement protein of endogenous factor VIII, no adverse effects on fertility are expected.

If patients experience dizziness or other symptoms affecting their ability to concentrate and react, it is recommended that they do not drive or use machines until the reaction subsides.

4.8 Undesirable effects

Summary of the safety profile

Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed and may in some cases progress to severe anaphylaxis (including shock).

Development of antibodies to mouse and hamster protein with related hypersensitivity reactions may

occur.

Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with IbliasIf such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.

Tabulated list of adverse reactions

The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level). Frequencies have been evaluated according to the following convention: common (> 1/100 to < 1/10), uncommon (> 1/1,000 to < 1/100).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table 2: Frequency of adverse drug reactions in clinical trials

Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients

includes injection site extravasation, hematoma, infusion site pain, pruritus, swelling

professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

No symptoms of overdose with recombinant human coagulation factor VIII have been reported.

5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antihemorrhagics: blood coagulation factor VIII, ATC code: B02BD02

Mechanism of action

The factor VIII/von Willebrand factor (vWF) complex consists of two molecules (factor VIII and vWF) with different physiological functions. When infused into a haemophiliac patient, factor VIII binds to vWF in the patient’s cir­culation. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Iblias does not contain von Willebrand factor.

Pharmacodynamic effects

The activated partial thromboplastin time (aPTT) is prolonged in people with haemophilia. Determination of aPTT is a conventional in vitro assay for biological activity of factor VIII. Treatment with rFVIII normalizes the aPTT similar to that achieved with plasma-derived factor VIII.

Clinical efficacy and safety

Control and Prevention of Bleeding

Two multi-center, open-label, cross-over, uncontrolled, randomized studies in previously treated adults/adolescents with severe haemophilia A (< 1%) and one multicenter, open label, uncontrolled study in previously treated children < 12 years with severe haemophilia A were conducted.

A total of 204 subjects have been included in the clinical trial program, 153 subjects > 12 years and 51 subjects < 12 years. 140 subjects were treated for at least 12 months, and 55 of these subjects for a median of 24 months.

Table 3: Consumption and overall success rates (patients treated with prophylaxis only)

Q1 first quartile; Q3 third quartile

BW: Body weight

*Success rate defined as % of bleeds treated successfully with =/< 2 infusions

5.2 Pharmacokinetic properties

The Pharmacokinetic (PK) profile of Iblias was evaluated in PTPs with severe haemophilia A following 50 IU/kg in 21 subjects > 18 years, 5 subjects > 12 years and < 18 years and 19 subjects < 12 years of age.

A population PK model was developed based on all available FVIII measurements (from dense PK sampling and all recovery samples) throughout the 3 clinical studies allowing calculation of PK parameters for subjects in the various studies. The table 4 below provides PK parameters based on the population PK model.

Table 4: PK parameters (geometric mean (%CV)) based on chromogenic assay.

* Based on population PK estimates

• AUC calculated for a dose of 50 IU/kg

Repeated PK measurements after 6 to 12 months of prophylaxis treatment with Iblias did not indicate any relevant changes in PK characteristics after long-term treatment.

J ?

In an international study involving 41 clinical laboratories, the performance of Iblias in FVIII:C assays was evaluated and compared to a marketed full length rFVIII product. Consistent results were determined for both products. The FVIII:C of Iblias can be measured in plasma with a one-stage coagulation assay as well as with a chromogenic assay using the routine methods of the laboratory.

The analysis of all recorded incremental recoveries in previously treated patients demonstrated a median rise of > 2% (> 2 IU/dL) per IU/kg body weight for Iblias. This result is similar to the reported values for factor VIII derived from human plasma. There was no relevant change over the 6–12 months treatment period.

Table 5: Phase III incremental recovery results

5.3 Preclinical safety data

Non-clinical data reveal no special risk for humans based on safety pharmacology, in vitro genotoxicity, and short term repeat-dose toxicity studies. Repeat-dose toxicity studies longer than 5 days, reproductive toxicity studies, and carcinogenicity studies, have not been performed. Such studies are not considered meaningful due to the production of antibodies against the heterologous human protein in animals. (Also FVIII is an intrinsic protein and not known to cause any reproductive or carcinogenic effects.)

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

PowJer

Sucrose

Histidine

Glycine

Sodium chloride

Calcium chloride

Polysorbate 80

Solvent

Water for injections

6.2 Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Only the provided infusion sets should be used for reconstitution and injection because treatment failure can occur as a consequence of human recombinant coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.

• 6.3 Shelf-life 30 months

The chemical and physical in-use stability after reconstitution has been demonstrated for 3 room temperature.

After reconstitution, from a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the resplity of the user.

Do not refrigerate after reconstitution.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Keep the vials in the outer carton in order to protect from light.

Within its overall shelf life of 30 months the product when kept in its outer carton, may be stored up to 25 °C for a limited period of 12 months. In this case, the product expires at the end of this 12-month period or the expiry date on the product vial, whichever is earlier. The new expiry date must be noted on the outer carton.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container and special equipment for use, administration or implantation

Each package of Iblias contains:

• • one vial with powder (10 mL clear glass type 1 vial with grey halogenobutyl rubber blend stopper and aluminium seal)
• • one vial with solvent (6 mL clear glass type 1 vial with grey chlorobutyl rubber blend stopper and aluminium seal)
• • an additional package with:

• – 1 filter transfer device 20/20 [Mix2Vial]

  
  

• – 1 venipuncture set

• – 1 disposable 5 mL syringe

• – 2 alcohol swabs for single use

6.6 Special precautions for disposal and other handling

Detailed instructions for preparation and administration are contained in the package leaflet provided with Iblias.

The reconstituted medicinal product is a clear and colourless solution.

Iblias powder should only be reconstituted with the supplied solvent (2.5 mL or 5 mL water for injections) using the supplied sterile vial filter transfer device. For infusion, the product must be prepared under aseptic conditions. If any component of the package is opened or damaged, do not use this component.

After reconstitution the solution is clear. Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. Do not use Iblias if you notice visible particulate matter or turbidity.

After reconstitution, the solution is drawn through the vial filter transfer device into the sterile disposable syringe (both supplied). Iblias should be reconstituted and administered with the components (vial adapter, vial with water for injections, disposable syringe, venipuncture set) provided with each package.

The reconstituted product must be filtered prior to administration to remove poten matter in the solution. Filtering is achieved by using the vial adapter.

For single use only.

Any unused medicinal product or waste material should be disposed of in accordan requirements.

7. MARKETING AUTHORISATION HOLDER

Bayer AG

51368 Leverkusen

Germany

8. MARKETING AUTHORISATION NUMBERS

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 18 February 2016